Skip to content
2000
Volume 23, Issue 4
  • ISSN: 1570-1611
  • E-ISSN: 1875-6212

Abstract

Purpose

The objective of this study was to explore the relationship among serum levels of the growth-stimulating expressed gene 2 protein (ST), Galectin-3 (GAL-3), N-terminal pro-B-type natriuretic peptide (NT-proBNP) in elderly hypertensive patients and heart failure with preserved ejection fraction (HFpEF).

Materials and Methods

Eighty-five elderly hypertensive patients with HFpEF were registered as the HFpEF group, and 46 hypertensive patients without HF were registered as the Non-HF group. The levels of serum sST2 (soluble ST2), Galectin-3, and NT-proBNP were measured, and related indexes of heart function were performed with echocardiography in two groups, respectively. The obtained variables were applied to statistical software for analysis.

Results

Age, BMI, SBP, DBP, TC, LDL-C, HCY, sST2, Galectin-3, NT- proBNP, LVEDD, IVSD, LVEF, and E/A were obviously different between the two groups (0.05). The levels of sST, Galectin-3 and NT- proBNP in the HFpEF group were higher than in the Non-HF group ( 0.05). ANOVA results indicated that sST2, Galectin-3, and NT- proBNP levels increased gradually with the increasing NYHA grades (0.05). BMI, SBP, DBP, TC, LDL-C, FBG, UA, HCY, LVEDD, IVSD, LVEF, and E/A were significant differences in patients with different NYHA classes ( 0.05). Spearman indicated that sST2, Galectin-3, and NT-proBNP were positively correlated with BMI, SDP, DBP, LDL-C, FBG, and HCY ( 0.05). Logistic analysis indicated that BMI, SBP, DBP, FBG, HCY, sST2, Galectin-3, NT-proBNP, LVEDD, LVEF, and E/A were risk factors for hypertension with HFpEF ( 0.05). ROC indicated that the AUC of the diagnostic performance of sST, Galectin-3, and NT-proBNP were all above 0.7, which may have some forecasting value for elderly hypertensive patients with HFpEF.

Conclusion

The levels of sST, Galectin-3, and NT-proBNP were closely related to cardiac function grades. sST2, Galectin-3, and NT-proBNP have similar diagnostic performance and predictive value for elderly hypertensive patients with HFpEF. sST2 was more sensitive than NT-proBNP. It is recommended that measurements of sST2, Galectin-3 and NT-proBNP levels in elderly hypertensive patients may be useful in classifying early HFpEF.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cvp/10.2174/0115701611315697241230075727
2025-01-24
2025-10-08

  • From This Site

    /content/journals/cvp/10.2174/0115701611315697241230075727
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LaticN. ErbenR.G. Vitamin D and cardiovascular disease, with emphasis on hypertension, atherosclerosis, and heart failure.Int. J. Mol. Sci.20202118648310.3390/ijms21186483 32899880
     [Google Scholar]
  2. KannelW.B. CastelliW.P. McNamaraP.M. McKeeP.A. FeinleibM. Role of blood pressure in the development of congestive heart failure. The Framingham study.N. Engl. J. Med.19722871678178710.1056/NEJM197210192871601 4262573
     [Google Scholar]
  3. McDonaghT.A. MetraM. AdamoM. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur. J. Heart Fail.2022241413110.1002/ejhf.2333 35083827
     [Google Scholar]
  4. ShahK.S. XuH. MatsouakaR.A. Heart failure with preserved, borderline, and reduced ejection fraction.J. Am. Coll. Cardiol.201770202476248610.1016/j.jacc.2017.08.074 29141781
     [Google Scholar]
  5. McDonaghT.A. MetraM. AdamoM. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur. Heart J.202142363599372610.1093/eurheartj/ehab368 34447992
     [Google Scholar]
  6. HayıroğluM.İ. ÇınarT. ÇiçekV. A simple formula to predict echocardiographic diastolic dysfunction—electrocardiographic diastolic index.Herz202146S2Suppl. 215916510.1007/s00059‑020‑04972‑6 32776316
     [Google Scholar]
  7. KeskinM. AvşarŞ. HayıroğluM.İ. Relation of the number of parity to left ventricular diastolic function in pregnancy.Am. J. Cardiol.2017120115415910.1016/j.amjcard.2017.03.244 28479168
     [Google Scholar]
  8. AgrawalV. HardasS. GujarH. PhalguneD.S. Correlation of serum ST2 levels with severity of diastolic dysfunction on echocardiography and findings on cardiac MRI in patients with heart failure with preserved ejection fraction.Indian Heart J.202274322923410.1016/j.ihj.2022.03.001 35278459
     [Google Scholar]
  9. YangY. LiuH. ZhangH. ST2/IL-33-dependent microglial response limits acute ischemic brain injury.J. Neurosci.201737184692470410.1523/JNEUROSCI.3233‑16.2017 28389473
     [Google Scholar]
  10. TsengC.C.S. HuibersM.M.H. GaykemaL.H. Soluble ST2 in end‐stage heart failure, before and after support with a left ventricular assist device.Eur. J. Clin. Invest.2018483e1288610.1111/eci.12886 29325227
     [Google Scholar]
  11. ZagidullinN. MotlochL.J. GareevaD. Combining novel biomarkers for risk stratification of two-year cardiovascular mortality in patients with st-elevation myocardial infarction.J. Clin. Med.20209255010.3390/jcm9020550 32085400
     [Google Scholar]
  12. Bayes-GenisA. CedielG. DomingoM. CodinaP. SantiagoE. LupónJ. Biomarkers in heart failure with preserved ejection fraction.Card. Fail. Rev.202288e2010.15420/cfr.2021.37 35815256
     [Google Scholar]
  13. ChirinosJ.A. OrlenkoA. ZhaoL. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction.J. Am. Coll. Cardiol.202075111281129510.1016/j.jacc.2019.12.069 32192654
     [Google Scholar]
  14. WuA.H.B. WiansF. JaffeA. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results.Am. Heart J.2013165699599910.1016/j.ahj.2013.02.029 23708172
     [Google Scholar]
  15. Michalska-KasiczakM. Bielecka-DabrowaA. von HaehlingS. AnkerS.D. RyszJ. BanachM. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: An overview.Arch. Med. Sci.201814489090910.5114/aoms.2018.76279 30002709
     [Google Scholar]
  16. JacobR. KhanM. BiomarkersC. Cardiac biomarkers: What is and what can be.Indian J. Cardiovasc. Dis. Women WINCARS20183424024410.1055/s‑0039‑1679104 31934672
     [Google Scholar]
  17. de BoerR.A. EdelmannF. Cohen-SolalA. MamasM.A. MaiselA. PieskeB. Galectin‐3 in heart failure with preserved ejection fraction.Eur. J. Heart Fail.201315101095110110.1093/eurjhf/hft077 23650131
     [Google Scholar]
  18. SharmaU.C. PokharelS. van BrakelT.J. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.Circulation2004110193121312810.1161/01.CIR.0000147181.65298.4D 15520318
     [Google Scholar]
  19. YuL. WillemP.T. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.Circ. Heart Fail.201361107117
     [Google Scholar]
  20. HoJ.E. LiuC. LyassA. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.J. Am. Coll. Cardiol.201260141249125610.1016/j.jacc.2012.04.053 22939561
     [Google Scholar]
  21. GopalD.M. KommineniM. AyalonN. Relationship of plasma galectin-3 to renal function in patients with heart failure: Effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.J. Am. Heart Assoc.201215e00076010.1161/JAHA.112.000760 23316284
     [Google Scholar]
  22. SunH.C. JinF. HouV.N. Correlation between serum Galectin-3 and Ptx-3 and clinical indicators of heart failure in DCM.Zhongguo Laonianxue Zazhi20204005912916
     [Google Scholar]
  23. GhorbaniA. BhambhaniV. ChristensonR.H. Longitudinal change in galectin‐3 and incident cardiovascular outcomes.J. Am. Coll. Cardiol.201872253246325410.1016/j.jacc.2018.09.076 30573026
     [Google Scholar]
  24. WatsonC.J. GallagherJ. WilkinsonM. Biomarker profiling for risk of future heart failure (HFpEF) development.J. Transl. Med.20211916110.1186/s12967‑021‑02735‑3 33563287
     [Google Scholar]
  25. TrippelT.D. MendeM. DüngenH.D. The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study.ESC Heart Fail.20218282984110.1002/ehf2.13174 33566456
     [Google Scholar]
  26. PuttM. HahnV.S. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab.Clin. Chem.201561911641172
     [Google Scholar]
  27. OkamotoR. HashizumeR. SuzukiN. Serum-induced expression of brain natriuretic peptide contributes to its increase in patients with hfpef.Int. J. Mol. Sci.2022236299110.3390/ijms23062991 35328412
     [Google Scholar]
  28. SimonW. The utility of growth differentiation factor-15, Galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: A systematic review.Heart Fail. Rev.2021619799812[J].
     [Google Scholar]
  29. ÇinierG. HayıroğluM.İ. KolakZ. The value of C‐reactive protein‐to‐albumin ratio in predicting long‐term mortality among HFrEF patients with implantable cardiac defibrillators.Eur. J. Clin. Invest.2021518e1355010.1111/eci.13550 33778950
     [Google Scholar]
  30. ÇinierG. HayıroğluM.İ. PayL. Prognostic nutritional index as the predictor of long‐term mortality among HFrEF patients with ICD.Pacing Clin. Electrophysiol.202144349049610.1111/pace.14170 33438766
     [Google Scholar]
  31. HayıroğluM.İ. ÇınarT. ÇinierG. Evaluating systemic immune‐inflammation index in patients with implantable cardioverter defibrillator for heart failure with reduced ejection fraction.Pacing Clin. Electrophysiol.202245218819510.1111/pace.14436 34978742
     [Google Scholar]
/content/journals/cvp/10.2174/0115701611315697241230075727
Loading
Association of ST2, Galectin-3, and NT- Probnp in Elderly Hypertensive Patients and Heart Failure with a Preserved Ejection Fraction
Curr. Vasc. Pharmacol. 23, 281 (2025); https://doi.org/10.2174/0115701611315697241230075727
/content/journals/cvp/10.2174/0115701611315697241230075727
/content/journals/cvp/10.2174/0115701611315697241230075727
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Galectin-3; HFpEF; LVEDD; LVEF; NT-proBNP; ST2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test